Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

by: Iola Bonggay

The United States Food and Drug Administration, otherwise referred to as the USFDA, an agency operating within the United States Department of Health and Human Services that is generally responsible for protecting and promoting public health through the regulation and supervision of food safety, tobacco products, dietary supplements, prescription and over-the-counter pharmaceutical drugs, vaccines, biopharmaceuticals, blood transfusions, medical devices, electromagnetic radiation emitting devices, veterinary products, and cosmetics.

The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

The primary goal of the program is to develop computational fluid dynamics (CFD) model of orally inhaled drug products that can account for drug product characteristics and physiological parameters on total and regional deposition in the lungs.

This is all in conjunction with the USFDA's objective of developing a CFD model that will be capable of of predicting highly localized deposition of pharmaceutically relevant polydisperse aerosols from metered dose inhalers (MDIs) and dry powder inhalers (DPIs).

In addition, the results that will be derived from this study will then be utilized to create a linked CFD-compartment model that can predict the effects of lung deposition on safety (systemic exposure) and efficacy (local delivery) for locally acting orally inhaled drugs.

  (continued...)

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
  Page 2

About The Author Iola Bonggay is an editor of TopGovernmentGrants.com one the the most comprehensive Websites offering information on government grants and federal government programs. She also maintains Websites providing resources on environmental grants and grants for youth programs.

Additional Resources

category - Health Grants

Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.
The USFA has recently formed a collaboration with the National Institutes of Health to establish the Predictive Lung Deposition Models for Safety and Efficacy of Orally Inhaled Drug Products Program.

---

Development of Therapeutics and Diagnostics for Biodefense Program
The National Institutes of Health, in partnership with the National Institute of Allergy and Infectious Diseases(NIAID), has established the Development of Therapeutics and Diagnostics for Biodefense Program in an attempt to seek research proposals that desire to support the development of lead candidate diagnostics or therapeutics against NIAID Category A, B, or C priority agents.

---

HIV Innovations for Improved Patient Outcomes for Priority Populations Program
The United States Agency for International Development in South Africa has recently established the HIV Innovations for Improved Patient Outcomes for Priority Populations Program wherein it intends to solicit applications coming from local organizations which are interested in heading the implementation of a five-year plan centered on the program in focus.

---

Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities
The National Institutes of Health has recently formed a partnership with the National Cancer Institute (NCI) in an effort to constitute the Exploratory/Developmental Grants Program for Basic Cancer Research in Cancer Health Disparities wherein both agencies intend to solicit grant application from various eligible researchers who are interested in conducing basic research studies regarding the biological causes and mechanisms of cancer health disparities.

---